Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel and estramustine
in treating patients who have metastatic prostate cancer.